Phase 4 N=40 Optimal Care of Complicated Appendicitis
Appendicitis · Perforated Appendicitis · Ruptured Appendicitis
Primary: Overall Cost of Care
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=333 Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
Complicated Urinary Tract Infection · Complicated Intra-abdominal Infection
Primary: Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set — 6; 8; 129; 132 Participant
Phase 4 N=467 Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection
Appendicitis · Cholecystitis · Cross Infection
Primary: Number of Clinically Evaluable Patients With Clinical Response of Cure at Test-of-Cure (TOC) Visit. — 133; 139 participants — p=0.009
N/A N=262 Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization
Osteomyelitis
Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants
Phase 2 N=201 Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Infections, Gram-positive Bacterial
Primary: Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 74; 72; 3; 5 participants — p=0.5318
Phase 3 N=804 Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem
Infection
Primary: Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population — 315; 324; 37; 23 participants
Phase 4 N=463 A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection
Intra-abdominal Infection
Primary: Clinical Response at the Test-of-Cure (TOC) Assessment Within the Clinically Evaluable (CE) Population — 89.9; 96.6; 10.1; 3.4 percentage of participants — p=0.0008
Phase 3 N=813 Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection
Abscess · Wound Infection · Diabetic Foot
Primary: Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population — 88.6; 89.6 percentage of…
Phase 2 N=143 Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections
Complicated Intra-abdominal Infection
Primary: Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the Test-of-Cure Visit — 39; 41; 24; 3 participants
Phase 2 N=32 Antibiotic Instillation in Appendicitis
Complicated Appendicitis · Acute Appendicitis
Primary: Feasibility of the Use of Antibiotic Solution Instillation Following Intraoperative Diagnosis of Complex Appendicitis as Assessed by Percentage of Eligible Participants…
N/A N=260 MICRO Study: Detecting Bacterial Infections Related to Orthopaedic Surgical Implants
Open Reduction and Internal Fixation of Extremity Fractures
Primary: Number of Blood Samples With High Levels of Absorbance Via ELISA for Patients (Greater Than 1.5 Ratio Compared to Control Human Serum) — 48; 53 blood draw samples
N/A N=418 Targeted Infection Control in Long-term Care
Infection
Primary: Total Number of MDRO (Multidrug Resistant Organisms) Isolated — 1299; 1732 Total Number of MDRO isolates — p=<0.05
N/A N=33 Enhanced, Personalized and Integrated Care for Infection Management at the Point-Of-Care
Antibiotic Resistant Infection · Infection
Primary: Percentage of Appropriate Antimicrobial Prescriptions Recommended — 90 percentage of prescriptions appropriate
Phase 3 N=259 Antibiotic Safety (SCAMP)
Complicated Intra Abdominal Infections
Primary: Death — 5; 5; 7; 1 Participants
N/A N=139 Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection
Abscess · Methicillin-Resistant Staphylococcus Aureus Infection
Primary: Recurrence Rates of Abscesses — 4; 14 participants
Phase 3 N=60 Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection
Complicated Intra-abdominal Infection
Primary: Number of Participants With Clinical Response at Test of Cure (TOC) Visit: Clinically Evaluable (CE) Analysis Set — 36; 4; 0 Participants
N/A N=3,153 COMBACTE-CDI Understanding the Burden of C. Difficile Infection
Clostridium Difficile Infection
Primary: The Number of Cases of CDI — 103; 0 Participants
Phase 2 N=169 Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Infections, Gram-Positive Bacterial · Abscess · Burns
Primary: Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 66; 66; 6; 3 participants — p=0.5289
Phase 2 N=1,310 Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Staphylococcal Infection
Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…
Phase 3 N=268 Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Complicated Intra-abdominal Infections
Primary: Percentage of Participants With Clinical Response (Clinical Cure or Clinical Failure) at Test of Cure (TOC) Visit: Clinically Evaluable (CE) Population — 95.2; 93.1…
Phase 3 N=458 Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection
Intraabdominal Infections
Primary: Number of Subjects With Adverse Events — 175; 82; 20; 6 Subjects
Phase 4 N=473 Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
Appendicitis · Cholecystitis · Diverticulitis
Primary: Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-Cure (TOC) Visit — 162; 150 participants
N/A N=180 Study Evaluating Severe Surgical Site Infections (SSIs) Following Contaminated Or Dirty-infected Abdominal Surgery
Surgical Wound Infection · Postoperative Wound Infection
Primary: Percentage of Participants With Pre-surgical Morbidities — 47.8; 48.9; 26.7; 23.3 percentage of participants — p=0.881
Phase 3 N=979 Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections
Complicated Intra-abdominal Infection
Primary: The Percentage of Subjects With Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population — 83.0; 87.3 percentage…
Phase 3 N=674 Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
Intra Abdominal Infections
Primary: Percentage of Participants With Clinical Success — 85.5; 90.2 percentage of participants
Phase 2 N=61 Multifaceted Treatment of Catheter-related Urinary Tract Infection
Spinal Cord Injury · Neurogenic Bladder · Urinary Tract Infection
Primary: The Primary Efficacy Outcome of the Study is Response to Treatment Which Will be Assessed at the End of Therapy. Successful Response to Treatment is Defined as…
N/A N=91 Topical Antibiotic Treatment for Spine Surgical Site Infection
Surgical Wound Infection
Primary: Surgeon Attitudes About Using Intra-wound Antibiotics for Spine Surgery — 9; 36; 46 Participants
N/A N=203 Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
Complicated Intra-Abdominal Infection
Primary: Duration of Hospitalization — 14.1 Days
Phase 2 N=204 Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
Complicated Intra-abdominal Infections
Primary: Number of Participants With Clinical Response at the Test of Cure (TOC) Visit — 62; 71 participants
Phase 3 N=100 Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)
Intra-abdominal Infection · Complicated Intra-abdominal Infection
Primary: Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at Test of Cure (TOC) — 92.0; 8.0; 0.0 Percentage of Participants